September 12, 2022
Research Report
Independent analysis
Report ID: 25202

noble

Cocrystal Pharma Inc. (COCP) - Influenza Program Update


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
3 min read
Get a Report
Refer to the full report for the price target, fundamental analysis, and rating.

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

The Company has attended Noble investor conference(s) in the last 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.


Cocrystal Pharma Inc.
Cocrystal Pharma Inc.
Healthcare
Biotechnology
Ticker
COCP
Current Price
$0.2741 -5.48%
Market Cap
$26.7M
Price Target
Refer to Report
Volume
280.0K
52wk Range
$0.2727 - $1.08
Related Research Reports
9/12/2022

Influenza Program Update
Influenza Program Update (COCP)
8/16/2022

2Q Reported With Influenza and COVID-19 Product Updates
2Q Reported With Influenza and COVID-19 Product Updates (COCP)
5/12/2022

Influenza Trial Continues With New Clinical Trials Planned For COVID-19
Influenza Trial Continues With New Clinical Trials Planned For COVID-19 (COCP)
4/13/2022

First Results From Influenza Program Announced
First Results From Influenza Program Announced (COCP)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.